Sarepta Therapeutics, Inc. (SRPT) Stock: Here’s What’s Happening


Sarepta Therapeutics, Inc. (SRPT) is headed down in the market in today’s trading session. The company, focused on the biotech sector, is presently priced at $132.98 after a move down of 0.00% so far in today’s session. When it comes to biotechnology companies, there are several factors that have the ability to lead to price movement in the market. News is one of the most common reasons for movement. Here are the recent stories surrounding SRPT:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-09-19 05:58AM Sarepta Therapeutics Sees Hammer Chart Pattern: Time to Buy?
Aug-08-19 04:35PM Why Zillow Group, Sarepta Therapeutics, and CenturyLink Slumped Today
04:26PM Sarepta stock tumbles after Duchenne gene therapy complication
04:08PM This Biotech Crashed On ‘Erroneous’ Report Plus 2 Stocks That Diverged
03:49PM Sarepta stock drops on erroneous adverse event report to FDA

Nonetheless, when making a decision with regard to investing, prospective investors should take a look at far more than news, especially in the speculative biotechnology sector. Here’s what’s going on with Sarepta Therapeutics, Inc..

Recent Movement Out of SRPT

While a decline in a single session, like the fall that we’re seeing from Sarepta Therapeutics, Inc. may make some investors tremble, that alone shouldn’t be the reason for a decision to, or not to, invest in a stock. It is generally a good idea to look into trends experienced by the stock for a period longer than a single session. In the case of SRPT, below are the returns that we have seen:

  • Past 5 Sessions – In the past week, SRPT has seen a price change amounting to -10.16%.
  • Past 30 Days – The monthly returns from Sarepta Therapeutics, Inc. has been -11.96%.
  • Past 3 Months – In the last three months, the stock has produced a ROI that comes to 11.80%
  • Bi-Annually – Throughout the previous 6 months, we have seen a change that works out to -3.25% from the stock.
  • This Year So Far – Since the close of last year SRPT has produced a return on investment of 21.85%.
  • Full Year – Finally, over the last full year, we have seen movement amounting to 9.48% from SRPT. In this period of time, the stock has sold at a high of -19.83% and a low price of 39.67%.

Key Ratios

Looking at a few key ratios having to do with a company can give prospective investors a look of just how risky and/or potentially profitable a pick might be. Below are a few of the key ratios to think about when digging into SRPT.

Short Ratio – The short ratio is a tool that is used by investors to get an understanding of the level of short interest. The higher this ratio, the more investors believe that the value of the stock is going to go down. In general, biotechnology stocks can come with a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the industry. Nonetheless, in relation to Sarepta Therapeutics, Inc., it’s short ratio comes to 10.81.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Basically, they measure the company’s abilities to pay for its debts as they mature with only quick assets or current assets. In the biotechnology space, many companies rely on continued investor support, the quick and current ratios can look damning. Nonetheless, some good picks in the biotechnology sector come with good quick and current ratios. As far as SRPT, the quick and current ratios add up to 11.10 and 12.20 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets that are owned by the company. In this particular case, the book to share value ratio works out to 18.80.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Many clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology sector, this is an important ratio to think about. In this case, the cash to share value is 17.90.

Analyst Opinions With Regard To Sarepta Therapeutics, Inc.

Although it’s never a smart idea to blindly follow the opinions of analysts, it is a good idea to consider their analysis when validating your own before making investment decisions in the biotech space. Here are the recent moves that we’ve seen from analysts with regard to SRPT.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-09-19 Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19 Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19 Initiated Evercore ISI Outperform
Mar-11-19 Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18 Initiated Bernstein Outperform

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in SRPT, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutions hold 95.90% of SRPT. However, it’s worth considering that institutional ownership has moved in the amount of 0.26% throughout the past 3 months.
  • Insider Holdings – as it relates to insiders, members of the management team and others close to SRPT currently own 0.30% of Sarepta Therapeutics, Inc.. Insider ownership of the company has seen a change of -4.25% over the past 3 months.

How Many Shares Of SRPT Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 75.11M shares of Sarepta Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, SRPT has a float of 70.51M.

I also like to dig into the short percentage of the float. After all, if a high portion of the float available for trading is shorted, the overall feeling among investors is that the company is headed for a deep dive. When it comes to SRPT, the short percentage of the float is currently 18.25%. Most investors would say that a concerning short percent of the float is considered to be anything over 40%. In my research, I have found that anything over 26% is generally a a play that could prove to be very risky.

What We’ve Seen In Financial Results

What have ween seen from SRPT in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – As it stands at the moment, analysts have expectations that the company will report earnings per diluted share that comes to -2.96, with -1.37 to be reported in the earnings announcement for the current quarter. Although this data is not based on earnings, because we are talking on the topic of analysts, Sarepta Therapeutics, Inc. is presently graded as a 1.70 on a scale from 1 to 5 where 1 is the worst possible Wall St. analyst rating and 5 is the best possible.
  • 5-Year Sales – Over the past half decade, Sarepta Therapeutics, Inc. has created a movement in revenue in the amount of 84.10%. Earnings per share in the past half decade have generated a change of -10.60%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings performance, or Q/Q data as it is generally represented in today’s society, the company has created a change in earnings in the amount of -95.30%. SRPT has also seen movement in regard to sales volume that amounts to 34.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an AI. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was created by a human and human beings actually play an important role in my ability to learn. Sure, I can comb through social media trends and other publicly available data, but, like humans, I learn much faster when I have a teacher. If you’d like to teach me something, I would love to learn! Is there other data that captures your interest? Should I say something differently? Is there another way to look at something? If so, leave a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here